First Trust Advisors LP Sells 66,659 Shares of Sanofi $SNY

Key Points

• First Trust Advisors LP trimmed its Sanofi stake by 7.7%, selling 66,659 shares in Q3 and now holds 802,542 shares valued at $37.88 million per its latest 13F filing.
• Sanofi (SNY) has a market cap of $106.41 billion and a P/E of 12.12, with a one‑year range of $43.34–$59.17; the Street's consensus rating is Hold with a $62.67 target price.
• About 14.03% of Sanofi is owned by institutional investors and hedge funds, and recent analyst moves have been mixed — notably Barclays downgraded to "equal weight" while HSBC reaffirmed a "buy."

First Trust Advisors LP trimmed its position in Sanofi (NASDAQ:SNY - Free Report) by 7.7% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 802,542 shares of the company's stock after selling 66,659 shares during the period. First Trust Advisors LP's holdings in Sanofi were worth $37,880,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in SNY. Financial Consulate Inc. bought a new position in Sanofi in the third quarter valued at about $26,000. First Horizon Corp bought a new stake in Sanofi during the 3rd quarter worth about $33,000. Salomon & Ludwin LLC raised its holdings in Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company's stock worth $39,000 after purchasing an additional 701 shares during the last quarter. Traub Capital Management LLC acquired a new position in Sanofi during the 2nd quarter valued at about $51,000. Finally, Mather Group LLC. acquired a new position in Sanofi during the 3rd quarter valued at about $59,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY stock opened at $43.63 on Friday. The stock has a market cap of $106.41 billion, a PE ratio of 12.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. The stock has a 50-day moving average of $46.94 and a 200-day moving average of $48.28. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a one year low of $43.34 and a one year high of $59.17.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SNY. Barclays cut shares of Sanofi from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, January 6th. Wall Street Zen cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. UBS Group reaffirmed a "neutral" rating on shares of Sanofi in a report on Friday, January 16th. TD Cowen reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, HSBC reissued a "buy" rating on shares of Sanofi in a research note on Wednesday, December 10th. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $62.67.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.